The prevalence and incidence of both diabetes and osteoporosis are increasing in the aging population. These diseases often coexist in older individuals, resulting in the loss of independence, disability, and mortality; this imposes a considerable healthcare burden worldwide. Complex pathophysiological interactions might exist between diabetes, osteoporosis, and their pharmacotherapies. Previous studies have suggested that diabetes could directly affect bone metabolism and bone quality through several mechanisms. Furthermore, several studies have discussed the potential effects of various antidiabetic medications on bone health and fracture risk. Meanwhile, relevant evidence on the effects of antiosteoporotic medications on glycemic control and diabetes risk also continues to accumulate. However, the current evidence, especially with respect to the relatively new medications for diabetes and osteoporosis (e.g., sodium-glucose co-transporters-2 inhibitor [SGLT2i], glucagon-like peptide 1 receptor agonist [GLP-1 RA], denosumab, and romosozumab), remains insufficient and controversial. Thus, real-world evidence on this issue is an urgent requirement.
This Research Topic aims to collect real-world evidence regarding the effects of pharmacotherapy of diabetes and osteoporosis on the risk and control of these diseases. Specifically, we welcome studies with the following topics for submissions: evaluation of the effects of various antidiabetic medications on bone health, effects of antiosteoporotic agents on diabetes and glycemic control, and potential drug-disease or drug-drug interactions between diabetes, osteoporosis/osteoporotic fracture, and related medications. Other studies related to pharmacotherapy of diabetes and osteoporosis/osteoporotic fracture could also be considered. We are particularly interested in studies with large-scale, nationwide, or population-based designs.
We are interested in the following types of manuscripts: original research, systematic review and meta-analysis, narrative review, and mini-review, with the following themes:
? Drug efficacy and safety
? Drug-drug interactions
? Drug-disease interactions
? Treatment outcomes
? Population data science
? Real-world data analysis
The prevalence and incidence of both diabetes and osteoporosis are increasing in the aging population. These diseases often coexist in older individuals, resulting in the loss of independence, disability, and mortality; this imposes a considerable healthcare burden worldwide. Complex pathophysiological interactions might exist between diabetes, osteoporosis, and their pharmacotherapies. Previous studies have suggested that diabetes could directly affect bone metabolism and bone quality through several mechanisms. Furthermore, several studies have discussed the potential effects of various antidiabetic medications on bone health and fracture risk. Meanwhile, relevant evidence on the effects of antiosteoporotic medications on glycemic control and diabetes risk also continues to accumulate. However, the current evidence, especially with respect to the relatively new medications for diabetes and osteoporosis (e.g., sodium-glucose co-transporters-2 inhibitor [SGLT2i], glucagon-like peptide 1 receptor agonist [GLP-1 RA], denosumab, and romosozumab), remains insufficient and controversial. Thus, real-world evidence on this issue is an urgent requirement.
This Research Topic aims to collect real-world evidence regarding the effects of pharmacotherapy of diabetes and osteoporosis on the risk and control of these diseases. Specifically, we welcome studies with the following topics for submissions: evaluation of the effects of various antidiabetic medications on bone health, effects of antiosteoporotic agents on diabetes and glycemic control, and potential drug-disease or drug-drug interactions between diabetes, osteoporosis/osteoporotic fracture, and related medications. Other studies related to pharmacotherapy of diabetes and osteoporosis/osteoporotic fracture could also be considered. We are particularly interested in studies with large-scale, nationwide, or population-based designs.
We are interested in the following types of manuscripts: original research, systematic review and meta-analysis, narrative review, and mini-review, with the following themes:
? Drug efficacy and safety
? Drug-drug interactions
? Drug-disease interactions
? Treatment outcomes
? Population data science
? Real-world data analysis